Hospital
City of Caribou
City of Caribou was paid $3.00M by Medicaid between Jan 2018 and Dec 2024, across 215 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoCITY OF CARIBOU
CARIBOU, ME 04736
CARIBOU, ME 04736
33aNPI1780615492assigned 07/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.00M
24GClaims533,938
24DCodes billed215
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maine
Rank by total paid#19 of 33
Median peer was paid$4.34M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 88,562 | $344K | |
| 2019 | 93,362 | $355K | |
| 2020 | 76,009 | $280K | |
| 2021 | 77,924 | $304K | |
| 2022 | 73,048 | $339K | |
| 2023 | 69,094 | $329K | |
| 2024incomplete | 55,939 | $1.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 30,789 | 28,520 | $775K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 18,032 | 16,590 | $679K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 10,829 | 9,688 | $461K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.7% | 5,687 | 5,379 | $172K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.3% | 8,544 | 5,299 | $129K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.7% | 5,727 | 3,339 | $82K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 4,773 | 4,450 | $65K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 6,257 | 5,456 | $65K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 3,749 | 3,495 | $52K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 12,046 | 10,647 | $52K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 11,183 | 3,040 | $50K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 5,394 | 4,957 | $31K |
203 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,053 | $30K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,294 | $28K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,499 | $26K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,651 | $25K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,543 | $18K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,763 | $18K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 597 | $16K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,411 | $13K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 506 | $12K |
| 59025 | Fetal non-stress test | <1% | 606 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,628 | $11K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,015 | $8K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 167 | $8K |
| 80053 | Comprehensive metabolic panel | <1% | 34,859 | $8K |
| 80061 | Lipid panel | <1% | 11,455 | $8K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,355 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,625 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,271 | $6K |
| 80050 | General health panel | <1% | 242 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 662 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,039 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 39,688 | $5K |
| 97161 | <1% | 947 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 292 | $5K |
| 73564 | <1% | 908 | $5K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 608 | $5K |
| 96367 | <1% | 1,126 | $4K | |
| 86900 | <1% | 1,651 | $4K | |
| 72100 | <1% | 897 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,358 | $4K |
| 71250 | <1% | 301 | $3K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 341 | $3K |
| 82607 | <1% | 4,525 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,836 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,425 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,594 | $3K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 42 | $3K |
| 82728 | <1% | 4,008 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,359 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 537 | $2K |
| 74018 | <1% | 340 | $2K | |
| 73630 | <1% | 814 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 153 | $1K |
| 71271 | <1% | 137 | $1K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 399 | $1K |
| 83550 | <1% | 3,134 | $1K | |
| 83880 | <1% | 2,327 | $1K | |
| 73030 | <1% | 432 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,596 | $1K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 256 | $1K |
| 87088 | <1% | 5,783 | $1K | |
| 83540 | <1% | 3,384 | $1K | |
| 83735 | <1% | 4,854 | $972.38 | |
| 82746 | <1% | 1,513 | $958.35 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 604 | $906.17 |
| 97162 | <1% | 210 | $887.68 | |
| 76830 | Ultrasound, transvaginal | <1% | 402 | $826.80 |
| 84439 | <1% | 1,232 | $779.71 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,234 | $750.84 |
| 82570 | <1% | 3,592 | $741.89 | |
| 87070 | <1% | 4,904 | $739.05 | |
| 82043 | <1% | 3,103 | $732.70 | |
| 73610 | <1% | 490 | $729.16 | |
| 87186 | <1% | 3,105 | $699.82 | |
| 96523 | <1% | 226 | $649.80 | |
| 73502 | <1% | 115 | $640.89 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,809 | $562.40 |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 172 | $559.47 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,810 | $559.35 |
| 77065 | Tomosynthesis, mammo | <1% | 54 | $535.74 |
| 73110 | <1% | 57 | $521.49 | |
| 85610 | <1% | 5,357 | $512.59 | |
| 76770 | <1% | 12 | $416.73 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 180 | $412.99 |
| 86803 | <1% | 664 | $408.80 | |
| 86140 | <1% | 2,807 | $399.06 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 203 | $383.47 |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,119 | $381.43 |
| 12001 | <1% | 13 | $380.58 | |
| 87631 | <1% | 526 | $380.58 | |
| 85651 | <1% | 4,125 | $332.86 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 98 | $331.60 |
| 86038 | <1% | 493 | $328.76 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 854 | $318.61 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $304.38 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 27 | $279.41 |
| 84153 | <1% | 603 | $248.02 | |
| 97014 | <1% | 386 | $227.71 | |
| 93971 | <1% | 27 | $220.10 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 103 | $204.61 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 49 | $198.80 |
| 94060 | <1% | 12 | $190.27 | |
| 84484 | <1% | 5,107 | $168.86 | |
| 81001 | <1% | 6,390 | $154.78 | |
| 93225 | <1% | 15 | $149.71 | |
| 83690 | <1% | 4,011 | $142.05 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 170 | $140.09 |
| Q3014 | Telehealth originating site facility fee | <1% | 24 | $138.80 |
| 83615 | <1% | 932 | $128.20 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 248 | $120.90 |
| 82550 | <1% | 1,224 | $107.96 | |
| 93017 | <1% | 79 | $107.77 | |
| 81003 | <1% | 6,349 | $97.86 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,004 | $97.30 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,802 | $96.21 |
| 97165 | <1% | 17 | $94.92 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 25 | $86.67 |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $76.41 |
| 73130 | <1% | 224 | $72.63 | |
| 84703 | <1% | 1,733 | $69.88 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 153 | $69.79 |
| 85379 | <1% | 1,733 | $66.60 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,335 | $66.04 |
| 82565 | <1% | 1,445 | $64.10 | |
| 86431 | <1% | 145 | $62.37 | |
| 82947 | <1% | 128 | $59.88 | |
| 86850 | <1% | 1,539 | $59.69 | |
| 86592 | <1% | 627 | $58.79 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 336 | $57.93 |
| 84132 | <1% | 440 | $55.82 | |
| 85045 | <1% | 517 | $52.00 | |
| 85730 | <1% | 1,423 | $51.24 | |
| 81015 | <1% | 300 | $48.02 | |
| 84100 | <1% | 845 | $46.35 | |
| 97116 | <1% | 39 | $46.30 | |
| 97035 | <1% | 47 | $35.57 | |
| 83605 | <1% | 2,379 | $28.97 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 896 | $27.06 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,829 | $26.27 |
| 81025 | <1% | 1,886 | $25.88 | |
| 87205 | <1% | 696 | $24.05 | |
| 87340 | <1% | 757 | $20.89 | |
| 77085 | <1% | 12 | $20.56 | |
| 87040 | <1% | 741 | $18.09 | |
| 84550 | <1% | 380 | $17.89 | |
| 84295 | <1% | 113 | $9.81 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,672 | $9.74 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 635 | $8.18 |
| G0378 | Hospital observation service, per hour | <1% | 756 | $7.77 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,664 | $6.67 |
| 84450 | <1% | 137 | $6.48 | |
| 80076 | <1% | 211 | $6.47 | |
| 85018 | <1% | 488 | $5.19 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,027 | $4.87 |
| 84165 | <1% | 15 | $3.57 | |
| 84520 | <1% | 145 | $3.45 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 44 | $2.90 |
| 85014 | <1% | 377 | $2.60 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 375 | $2.11 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 53 | $0.17 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 12 | $0.00 |
| J3490 | Unclassified drugs | 0% | 16,965 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 861 | $0.00 |
| 96376 | 0% | 1,042 | $0.00 | |
| 86901 | 0% | 1,733 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 168 | $0.00 |
| 87807 | 0% | 66 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 4,684 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 595 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 3,043 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 3,170 | $0.00 |
| 80349 | 0% | 483 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 3,523 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 606 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 742 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 535 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 99 | $0.00 |
| 86762 | 0% | 240 | $0.00 | |
| 82950 | 0% | 41 | $0.00 | |
| 76820 | 0% | 64 | $0.00 | |
| 82150 | 0% | 120 | $0.00 | |
| 82784 | 0% | 42 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 77 | $0.00 |
| 86706 | 0% | 26 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 95 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 62 | $0.00 |
| 82435 | 0% | 80 | $0.00 | |
| 82378 | 0% | 12 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 25 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 484 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 371 | $0.00 |
| 88312 | 0% | 353 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 465 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 670 | $0.00 |
| 84702 | 0% | 186 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 337 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 436 | $0.00 |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 0% | 59 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 286 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 47 | $0.00 |
| 84156 | 0% | 82 | $0.00 | |
| 82747 | 0% | 27 | $0.00 | |
| 84460 | 0% | 76 | $0.00 | |
| 82140 | 0% | 134 | $0.00 | |
| 87210 | 0% | 13 | $0.00 | |
| 90715 | 0% | 131 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 133 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 27 | $0.00 |
| 87185 | 0% | 28 | $0.00 | |
| 83970 | 0% | 16 | $0.00 | |
| 86200 | 0% | 12 | $0.00 | |
| 84403 | 0% | 25 | $0.00 | |
| 93226 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOODY, KRIS (CHEIF EXECUTIVE OFFICER)